Literature DB >> 6751836

Effect of three angiotensin II antagonists, [Sar1, Thr8]-, [Sar1, Ile8]- and [Sar1, Ala8]angiotensin II on blood pressure and endocrine factors in normal subjects.

T Hata, T Ogihara, M Nakamaru, S Gotoh, K Masuo, S Saeki, A Kumagai, Y Kumahara.   

Abstract

The biological effects of 1-Sarcosine, 8-Threonine angiotensin II ([Sar1, Thr8]ANG II) on blood pressure, plasma aldosterone concentration (PAC) and plasma renin activity (PRA) were investigated in six normal subjects on an unrestricted diet, and compared with those of 1-Sarcosine, 8-Isoleucine ANG II ([Sar1, Ile8]ANG II) and 1-Sarcosine, 8-Alanine ANG II ([Sar1, Ala8]ANG II). All three ANG II analogues (AIIA) showed agonistic pressor activity, that of [Sar1, Ile8]ANG II being greater than that of [Sar1, Thr8]ANG II or [Sar1, Ala8]ANG II. The antagonistic effect of [Sar1, Thr8]ANG II on blood pressure was less than [Sar1, I1e8]ANG II or [Sar1, Ala8]ANG II. Both [Sar1, Ile8]ANG II and [Sar1, Ala8]ANG II increased PAC and blocked the steroidogenic action of ANG II, while [Sar1, Thr8]ANG II showed little effect on PAC. All three AIIA caused similar suppression of PRA and showed no inhibitory effect on the decrease in PRA produced by ANG II. These results indicate that [Sar1, Thr8]ANG II is an AIIA with weak agonistic pressor action and that it has vascular selective properties. It is also suggested that ANG II receptors in a variety of target organs are heterogeneous.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6751836     DOI: 10.1007/bf01061369

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  19 in total

1.  Effects of two angiotensin II analogous on blood pressure in normal subjects with various sodium balances.

Authors:  T Ogihara; T Hata; H Mikami; T Mandai; Y Kumahara
Journal:  Life Sci       Date:  1977-06-01       Impact factor: 5.037

2.  Agonist and antagonist relationships in 1- and 8-substituted analogs of angiotensin II.

Authors:  M C Khosla; M M Hall; R R Smeby; F M Bumpus
Journal:  J Med Chem       Date:  1974-11       Impact factor: 7.446

Review 3.  Pharmacology of angiotensin.

Authors:  D Regoli; W K Park; F Rioux
Journal:  Pharmacol Rev       Date:  1974-06       Impact factor: 25.468

4.  Angiotensin-II blockade in man by sar1-ala8-angiotensin II for understanding and treatment of high blood-pressure.

Authors:  H R Brunner; H Gavras; J H Laragh
Journal:  Lancet       Date:  1973-11-10       Impact factor: 79.321

5.  Hemodynamics of a new angiotensin antagonist, [Sar1, Thr8]A II, in hypertensive man.

Authors:  R J Cody; R C Tarazi; F M Fouad; E L Bravo
Journal:  Circulation       Date:  1980-02       Impact factor: 29.690

6.  Use of an angiotensin II antagonist (saralasin) in the recognition of "angiotensinogenic" hypertension;.

Authors:  D H Streeten; G H Anderson; J M Freiberg; T G Dalakos
Journal:  N Engl J Med       Date:  1975-03-27       Impact factor: 91.245

7.  Action of (1-des(aspartic acid), 8-isoleucine) angiotensin II upon the pressor and steroidogenic activity of angiotensin II.

Authors:  E L Bravo; M C Khosla; F M Bumpus
Journal:  J Clin Endocrinol Metab       Date:  1975-03       Impact factor: 5.958

8.  Blockade and stimulation of renal, adrenal, and vascular angiotensin II receptors with 1-Sar, 8-Ala angiotensin II in normal man.

Authors:  N K Hollenberg; G H Williams; B Burger; I Ishikawa; D F Adams
Journal:  J Clin Invest       Date:  1976-01       Impact factor: 14.808

9.  Usefulness and limitations of saralasin, a partial competitive agonist of angioten II, for evaluating the renin and sodium factors in hypertensive patients.

Authors:  D B Case; J M Wallace; H J Keim; J E Sealey; J H Laragh
Journal:  Am J Med       Date:  1976-05-31       Impact factor: 4.965

10.  Effects of two angiotensin II analogues on blood pressure, plasma aldosterone concentration, plasma renin activity and creatinine clearance in normal subjects on different sodium intakes.

Authors:  T Hata; T Ogihara; H Mikami; M Nakamaru; T Mandai; Y Kumahara
Journal:  Eur J Clin Pharmacol       Date:  1980-10       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.